pemazyre
incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - agenți antineoplazici - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
pemazyre 13,5 mg
incyte biosciences distribution b.v. - tarile de jos - pemigatinibum - compr. - 13,5mg - inhibitori de protein-kinaza
pemazyre 13,5 mg
incyte biosciences distribution b.v. - tarile de jos - pemigatinibum - compr. - 13,5mg - inhibitori de protein-kinaza
pemazyre 4,5 mg
incyte biosciences distribution b.v. - tarile de jos - pemigatinibum - compr. - 4,5mg - inhibitori de protein-kinaza
pemazyre 9 mg
incyte biosciences distribution b.v. - tarile de jos - pemigatinibum - compr. - 9mg - inhibitori de protein-kinaza